GRAL - NASDAQ
GRAIL, Inc.
$66.93
+9.5%GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
At a Glance
Live Snapshotgral
Other Non-Current Assets
Last Annual Value
6.75M
3-Year CAGR
3%
5-Year CAGR
-1%
10-Year CAGR
9%
GRAIL, Inc. Competitors Analysis of Other Non-Current Assets
| Company | Other Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
GRAIL, Inc. NASDAQ:GRAL | 6.75M | -5.4% | -1.0% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 200.78M | 967.6% | 449.7% | 109.1% | |
 Celcuity Inc. NASDAQ:CELC | 349.00K | N/A | N/A | N/A | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 35.00M | -15.3% | 11.2% | N/A | |
 Envista Holdings Corp NYSE:NVST | 228.10M | 8.1% | 6.3% | N/A | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 181.40M | 667.7% | N/A | N/A | |
 IDEAYA Biosciences, Inc. NASDAQ:IDYA | 411.31M | 707.2% | 300.9% | N/A | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 15.60M | 88.9% | 46.5% | -37.3% |
GRAIL, Inc. Fair Value Envelope
Related Guides
Continue your GRAL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.